Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Levocarnitine Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionyl-Carnitine SCHEMBL3639171 | 1.00 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL3637409 | 0.99 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL3637406 | 0.99 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL19617435 | 0.92 | MEN1 (0.90) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL464940 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL156850 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL994714 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL1358526 | 0.89 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL3005249 | 0.89 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL1358528 | 0.89 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | claimed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021221741-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | LONZA CONSUMER HEALTH INC. (US) | 2021-11-04 | — | — | WO | claimed |
| EP-2877194-A1 | COMPOSITIONS AND METHODS FOR INCREASING CARNITINE LEVEL IN MUSCLE TISSUES | Oneday - Biotech And Pharma Ltd. (IL) | 2015-06-03 | — | — | EP | claimed |
| WO-2014016837-A1 | COMPOSITIONS AND METHODS FOR INCREASING CARNITINE LEVEL IN MUSCLE TISSUES | ONEDAY - BIOTECH AND PHARMA LTD. (IL) | 2014-01-30 | — | — | WO | claimed |
| CN-122070931-A | Injection composition for lipolysis | 姜旼材 | 2026-05-22 | — | — | CN | disclosed |
| US-20260137761-A1 | INJECTION COMPOSITION FOR LIPOLYSIS | KANG MIN JAE (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-4125858-B1 | NUTRITIONAL COMPOSITION COMPRISING L-CARNITINE TARTRATE FOR USE IN TREATING OR PREVENTING A CORONAVIRUS INFECTION IN A MAMMAL | LONZA GREENWOOD LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4637740-A1 | COMBINATIONS OF A UROTHILIN AND A KETONE BODY | Amazentis SA (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4566601-A2 | METHODS FOR IMPROVING MITOPHAGY IN SUBJECTS | Amazentis SA (CH) | 2025-06-11 | — | — | EP | disclosed |
| EP-4551232-A1 | METABOLOMIC IMPROVEMENTS USING RESISTANT STARCH SUPPLEMENTATION | Mcpharma Biotech Inc. (CA) | 2025-05-14 | — | — | EP | disclosed |
| EP-4553071-A2 | METHODS FOR IMPROVING MITOPHAGY IN SUBJECTS | Amazentis SA (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2013175386-A1 | COMPOSITIONS AND METHODS FOR INCREASING STRENGTH AND MUSCLE MASS | CHEMI NUTRA INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20100080856-A1 | Method and composition for postoperative wound healing | COSTANTINO PETER D | 2010-04-01 | — | — | US | disclosed |
| EP-2152225-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-02-17 | — | — | EP | disclosed |
| EP-2152225-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-02-17 | — | — | EP | disclosed |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | disclosed |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, CUTA | MEN1 3124/4885KMT2A 3957/4885CYP2C19 2896/4885 |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, UGCG | MEN1 3282/4885KMT2A 3926/4885CYP2C19 2774/4885 |
| US-20260137761-A1 | INJECTION COMPOSITION FOR LIPOLYSIS | LPL, LIPE, LIPG | MEN1 4732/4885KMT2A 1433/4885CYP2C19 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.